Metforal

Metformin Hydrochloride, the active ingredient in Metforal, is a Biguanide presented as an oral tablet for oral administration. It works by decreasing hepatic glucose production and improving peripheral insulin sensitivity, thereby helping adults with type 2 diabetes mellitus achieve better glycemic control.

GNH USA supplies Metforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global distribution. The company adheres to stringent manufacturing standards and provides reliable logistics support for cross‑border procurement.

Metforal is a Biguanide oral antidiabetic that acts on glucose metabolism pathways.

Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. Polycystic ovary syndrome (PCOS): reduces insulin resistance, which can help restore ovulatory function under medical supervision. Impaired glucose tolerance: lowers elevated fasting glucose and delays progression to overt diabetes when prescribed by a healthcare professional.

Metforal may cause a range of adverse reactions, most of which are related to gastrointestinal tolerance and metabolic disturbances.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools, especially during dose titration. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: rare liver dysfunction that may exacerbate metabolic complications.

Metforal requires careful patient assessment and monitoring to minimize risks. - Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal, hepatic, or cardiac impairment. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Contrast imaging: discontinue metformin before and after iodinated contrast procedures as advised. - Pregnancy and lactation: use only if clearly needed and prescribed by a qualified clinician. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Metforal can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis. - Cimetidine: increases metformin plasma concentrations. - Alcohol: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics: can affect renal clearance of metformin, requiring dose adjustment.